CD8A and neoplasm: Activated DCs phagocytose tumor-associated antigens (TAAs) and present them to CD4+ and CD8+ T cells via major histocompatibility complex (MHC) molecules, promoting T cell proliferation, differentiation, and effector functions, thereby eliciting a specific antitumor immune response (26).